Back

Prevalence of obesity and associated long-term cardiovascular risk in a modern Swedish population with acute myocardial infarction with and without diabetes

29 August 2025 (15:15 - 16:00)
Organised by: Logo
Congress Presentation Part of: Epidemiology in acute coronary syndromes (1) Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Viveca Ritsinger

Karolinska Institute, Stockholm (Sweden)

6 More presentations in this session

Presentation thumbnail
The impact of off-hours presentation on outcome in patients with acute coronary syndrome complicated by cardiogenic shock
Doctor Y. Nobushima (Izunokuni, JP)
Abstract Slides Video
Presentation thumbnail
5-year mortality after ST-segment elevation myocardial infarction compared to the general population
Ms Y. Huang (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Care and outcomes of first-time myocardial infarction across potentially vulnerable populations: temporal trends from 2003-2022
Miss C. Friis (Gentofte, DK)
Abstract Slides Video
Presentation thumbnail
Prognostic impact of patterns of in-hospital heart failure on clinical outcomes after myocardial infarction
Doctor S. Okita (Chiba, JP)
Abstract Slides Video
Presentation thumbnail
A systematic-scoping review on sex-based differences in type-2 myocardial infarction (T2MI)
Doctor M. Yordanova (Montreal, CA)
Abstract Slides Video

Access the full session

Session thumbnail
Epidemiology in acute coronary syndromes (1)

The Event

Event poster

ESC Congress 2025

29 August 2025 15:15 CET
You may be interested in
thumbnail
Congress Presentation
Extent and impact of obesity in patients with diabetes and acute myocardial infarction - experience from a national cohort
thumbnail
Congress Presentation
Impact of body mass index and prediabetes on the risk of type 2 diabetes and cardiovascular events following a recent myocardial infarction
thumbnail
Congress Session
Challenges of managing obesity in cardiovascular disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources